Coverage of Coronavirus Disease-2019 (COVID-19) Booster Dose (Precautionary) in the Adult Population: An Online Survey

Ramesh Masthi NR 1, Anagha Brahmajosyula 1, Aniket Khamar 1, Namita Acharya 1, Lavanya P. Bilichod 1, Deepika Kondath 1

1. Department of Community Medicine, Kempegowda Institute of Medical Sciences, Bangalore, IND

Abstract

Background

The coronavirus disease-2019 (COVID-19) pandemic devastated public health worldwide, including India. COVID-19 vaccines and their boosters are life-saving developments that have helped prevent and control the spread of COVID-19. We conducted this study to assess the coverage of the booster dose in an Indian population (the third dose of the COVID-19 vaccine in India is referred to as the booster or precautionary dose), record the reasons for not taking the booster dose, and determine the effectiveness of the booster. The levels of adherence to COVID-19 precautionary behavior was also assessed.

Methods

We conducted a descriptive, cross-sectional study using convenient sampling via an online survey of 550 respondents older than 18 in the second quarter of 2022. The respondents were distributed among 18 states and union territories in India. The data were analyzed as simple proportions and percentages.

Results

Of the 550 respondents, 152 (27.6%) received the booster dose, indicating low coverage. A small percentage of respondents (7.2%) reported suffering from COVID-19 following the booster, of whom 91% were medical professionals. The most common reported reason for not taking the vaccine was that the respondents were not yet due for their dose (48.1%). The time between the second dose of the COVID-19 vaccine and the booster had no impact on infection rates. Men were less likely to adhere to COVID-19 precautionary behavior than women, despite similar vaccination rates.

Conclusion

The COVID-19 vaccine booster had a low acceptance in our study population, with roughly one-quarter of the population receiving the booster. The booster dose has been influential in the prevention of COVID-19. Most respondents followed behavioral safety measures despite the decline of active cases of COVID-19 in India following the Omicron wave. Our results indicate a need to strengthen public strategies to affect behavioral changes, such as improving India’s Behavior Change Communication program to ensure adequate booster dose coverage.

Categories: Preventive Medicine, Infectious Disease, Epidemiology/Public Health

Keywords: covaxin, covishield, covid-19 vaccine india, covid vaccination booster, sars-cov-2, covid-19 vaccine efficacy, covid-19 india

Introduction

In December 2019, an outbreak of the novel coronavirus disease-2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was initially detected in Wuhan, China. The first case in India was reported on January 27, 2020 [1]. Subsequently, it was declared a pandemic on March 11, 2020, by the World Health Organization [2]. In India, COVID-19 affected approximately 43 million people and has contributed to 524,706 deaths as of June 6, 2022 [3].

The COVID-19 vaccine was introduced in India on January 16, 2021, for the health care workers, frontline workers, and older patients (aged 60 years or older), and subsequently in different age groups in a phased manner [4]. The vaccines currently approved (as of June 6, 2022) for booster dose in India are Covishield (AstraZeneca, manufactured by Serum Institute of India Private Ltd., Pune, India) and Covaxin (Bharat Biotech International Ltd., Hyderabad, India) [5]. Since the vaccines’ introduction, 74% of the population has received the first dose, and 65% have received the second dose since June 6, 2022 [6].

A booster dose (i.e., a precautionary dose) was introduced in India for the health care workers, frontline workers, patients older than age 50, and those with comorbidities (Phase 1) on January 10, 2022 [7]. The Government of India announced the booster dose for patients aged 18 or older on April 10, 2022 [8]. The booster dose effectively prevented and controlled the spread of COVID-19 [9]. However, the decline in the number of active cases coincided with apprehension regarding the booster dose. Since the Omicron variant wave subsided in India, adherence to COVID-19 precautionary behavior (e.g., social distancing, mask-
vaccine, and only three (0.5%) respondents reported taking only one dose of the vaccine. The remaining Sputnik vaccines. Nearly all respondents (544, 98.9%) reported receiving two doses of the COVID-19 received Covaxin. Three (0.5%) received the Pfizer vaccine and two (0.4%) each received the Moderna and

Most respondents (n = 454, 82.5%) received the CoviShield vaccine as the primary dose, and 89 (16.3%) (2.7%) from other nonmedical sectors. There were nine respondents (0.2%) response each. The remaining seven (1.3%) responses were collected from other parts of the country. The study received responses from 18 states and other union territories across India. Most respondents (n = 369; 67.1%) were from Karnataka; 46 responses (8.4%) came from Gujarat; 25 (4.5%) from Telangana; 22 (4.1%) from Maharashtra; 19 (3.5%) from Tamil Nadu; 18 (3.3%) from Kerala; 14 (2.5%) from West Bengal; seven (1.3%) from Uttar Pradesh; five (0.9%) each from Andhra Pradesh, Chhattisgarh, and Punjab; and two (0.4%) professionals, one (0.6%) was a paramedic, and one (0.6%) was a paramedical student. Of the 395 respondents was 39 years. The median age of the respondents was 59 years.

The study involved an online survey using Google Forms (Google, Mountain View, CA, USA) on respondents aged 18 years or older, living across the different states of India, representing a large geographical area. The sample size was calculated based on a pilot study coverage using the formula $4pq^2$, where prevalence ($p$) = 14 and $q$ ($1-p$) = 86, and precision ($r$) = 5. The calculated sample size was 535, rounded to 550 respondents. We used a convenient sampling technique for the collection of responses. The investigators shared the questionnaire with their known contacts, who, in turn, shared it with their contacts until the sample size was met by snowball sampling. Only those respondents who had access to the internet and smartphones were part of the study.

The questionnaire consisted of 16 questions, semistructured with open- and closed-ended questions on the demographic information, vaccination status, booster dose, reasons for not taking the booster, history of SARS-CoV-2 infection, existing comorbidities, and adherence to COVID-19 precautionary behavior (see Appendix). Study participation was voluntary. All participants provided informed consent, and the Institutional Ethics Committee of Kempegowda Institute of Medical Sciences approved the questionnaire (reference number KIMS/IEC/A027/M/2022). Confidentiality was ensured so that only authorized persons had access to the data.

The results were analyzed appropriately using Google Spreadsheets (Google, Mountain View, CA, USA), and data were cleansed. The data were described in terms of median, percentages, proportions, graphs and Z-tests to determine significance. The data were considered statistically significant at $p < 0.05$.

A total of 550 respondents aged 18 or older were included in the study (275 men (50%); 272 women (49.5%); two respondents (0.3%) declined to disclose sex, and one (0.2%) was transgender). Most respondents (n = 258; 43.3%) were aged 18 to 30, 42 (7.6%) were aged 31 to 40, 166 (30.2%) were aged 41 to 50, 81 (14.7%) were aged 51 to 60, 23 (4.18%) were older than 60, and two (0.36%) were aged 81 or older. The median age of the respondents was 39 years.

The study was conducted in the second quarter of 2022. The study involved an online survey using Google Forms (Google, Mountain View, CA, USA) on respondents aged 18 years or older, living across the different states of India, representing a large geographical area. The sample size was calculated based on a pilot study coverage using the formula $4pq^2$, where prevalence ($p$) = 14 and $q$ ($1-p$) = 86, and precision ($r$) = 5. The calculated sample size was 535, rounded to 550 respondents. We used a convenient sampling technique for the collection of responses. The investigators shared the questionnaire with their known contacts, who, in turn, shared it with their contacts until the sample size was met by snowball sampling. Only those respondents who had access to the internet and smartphones were part of the study.

The questionnaire consisted of 16 questions, semistructured with open- and closed-ended questions on the demographic information, vaccination status, booster dose, reasons for not taking the booster, history of SARS-CoV-2 infection, existing comorbidities, and adherence to COVID-19 precautionary behavior (see Appendix). Study participation was voluntary. All participants provided informed consent, and the Institutional Ethics Committee of Kempegowda Institute of Medical Sciences approved the questionnaire (reference number KIMS/IEC/A027/M/2022). Confidentiality was ensured so that only authorized persons had access to the data.

The results were analyzed appropriately using Google Spreadsheets (Google, Mountain View, CA, USA), and data were cleansed. The data were described in terms of median, percentages, proportions, graphs and Z-tests to determine significance. The data were considered statistically significant at $p < 0.05$.

A total of 550 respondents aged 18 or older were included in the study (275 men (50%); 272 women (49.5%); two respondents (0.3%) declined to disclose sex, and one (0.2%) was transgender). Most respondents (n = 258; 43.3%) were aged 18 to 30, 42 (7.6%) were aged 31 to 40, 166 (30.2%) were aged 41 to 50, 81 (14.7%) were aged 51 to 60, 23 (4.18%) were older than 60, and two (0.36%) were aged 81 or older. The median age of the respondents was 39 years.

The study received responses from 18 states and other union territories across India. Most respondents (n = 369; 67.1%) were from Karnataka; 46 responses (8.4%) came from Gujarat; 25 (4.5%) from Telangana; 22 (4.1%) from Maharashtra; 19 (3.5%) from Tamil Nadu; 18 (3.3%) from Kerala; 14 (2.5%) from West Bengal; seven (1.3%) from Uttar Pradesh; five (0.9%) each from Andhra Pradesh, Chhattisgarh, and Punjab; and two (0.4%) responses were from Haryana. Assam, Goa, Jharkhand, Madhya Pradesh, Rajasthan, and Sikkim had one (0.2%) response each. The remaining seven (1.3%) responses were collected from other parts of the country.

One hundred eighty-three respondents (32.9%) were graduates, 174 (31.63%) had a professional degree or were postgraduates, 175 (31.8%) were undergraduates, 16 (2.9%) were 12th pass/second pre-university course, and two (0.36%) had completed high school. Many respondents (n = 155, 28.2%) were medical, and allied professionals (e.g., doctors, students, nursing professionals, dentists, and paramedical professionals), and 395 (71.8%) were from various occupations in nonmedical sectors. Of the 155 medical and allied professionals, 125 (80.6%) were medical students, 24 (15.6%) were medical doctors, four (2.6%) were nursing professionals, one (0.6%) was a paramedic, and one (0.6%) was a paramedical student. Of the 395 nonmedical professionals, most (n = 68, 17.2%) were in information technology, civil engineering, automation, telecommunication, and aeronautics; 62 (15.7%) were homemakers; 55 (14%) were from the business sector; 50 (12.6%) were students (e.g., engineering, commerce); 38 (9.6%) were teachers/professors; 37 (9.4%) were salaried professionals; 12 (3%) were in the industrial sector; six (1.5%) were in the public services sector; five (1.2%) were in the marketing sector; 11 (2.7%) were from the legal and administrative sectors; five (1.2%) were architects; one (0.3%) was from arts sector; two (0.5%) respondents each were from the commerce industry, the agricultural sector, and media and journalism sector. 16 of the respondents (4%) reported to not working presently and 14 (3.5%) were reported to have retired. There were nine respondents (2.7%) from other nonmedical sectors.

Most respondents (n = 454, 82.5%) received the CoviShield vaccine as the primary dose, and 89 (16.3%) received Covaxin. Three (0.5%) received the Pfizer vaccine and two (0.4%) each received the Moderna and Sputnik vaccines. Nearly all respondents (544, 98.9%) reported receiving two doses of the COVID-19 vaccine, and only three (0.5%) respondents reported taking only one dose of the vaccine. The remaining three did not receive any vaccine doses (Figure 1).
OF the 152 (27.6%) respondents who received a booster dose, most (n = 75) were aged between 18 to 30. Only six respondents aged 31 to 40 reported receiving a booster dose (Table 1). 83 respondents (54.6%) were medical and allied professionals, and 69 (45.4%) were nonmedical professionals (Z = 8.434, p < 0.05). Thus, the booster coverage was 53.5% among medical and allied professionals and 17.5% among nonmedical professionals. Among the medical and allied professionals, 10 (12.0%) developed COVID-19 following the booster dose, and among the nonmedical respondents, only one (1.4%) developed COVID-19 afterwards. Of the 23 respondents aged 60 years and above, 18 (78.3%) received the booster dose, and none later developed COVID-19.

| Age (years) | Booster Received, n (%) | No Booster Received, n (%) | Total N (%) |
|-------------|-------------------------|----------------------------|-------------|
| 18-30       | 75 (31.5%)              | 163 (68.5%)                | 238 (100%)  |
| 31-40       | 6 (14.3%)               | 36 (85.7%)                 | 42 (100%)   |
| 41-50       | 31 (18.7%)              | 135 (81.3%)                | 166 (100%)  |
| 51-60       | 22 (27.2%)              | 59 (72.8%)                 | 81 (100%)   |
| 60 and above| 18 (78.2%)              | 5 (21.7%)                  | 23 (100%)   |
| TOTAL       | 152                     | 398                        | 550 (100%)  |

**TABLE 1: Age distribution of the respondents with booster status (N = 550)**

Table 2 presents the time between the second vaccine dose and the booster. Most (n = 76, 50%) respondents received the booster nine to 12 months after the second vaccine dose, and 37 respondents (24.3%) reported receiving the booster six to nine months after their second dose of the vaccine.
| Time Between Second Dose and Booster | Respondents, n | Respondents with COVID-19 After Booster, n (%) |
|--------------------------------------|----------------|-----------------------------------------------|
| 1-3 months                           | 6              | -                                             |
| 3-6 months                           | 13             | 1 (7.7%)                                      |
| 6-9 months                           | 37             | 3 (8.1%)                                      |
| 9-12 months                          | 76             | 6 (7.9%)                                      |
| 12-14 months                         | 19             | 1 (5.3%)                                      |
| > 14 months                          | 2              | -                                             |

### TABLE 2: Comparison of respondents with booster dose and COVID-19 over time (n = 152)
COVID-19: coronavirus disease-2019

Reasons for not yet receiving the booster are presented in Table 3. Most (n = 188, 48.1%) claimed they were not yet due for their booster dose. The next most cited reason (n = 41, 10.4%) was the apparent unavailability of the vaccine at the vaccine centers and the lack of slot availability on the COVID-19 Vaccine Intelligence Network portal [15]. The least cited reason (n = 2, 0.5%) was adverse events following the previous dose.

| Reason                                                | Medical and Allied Professionals, n (%) | Nonmedical Professionals, n (%) | Respondents, n (%) | Z value (at p < 0.05) |
|-------------------------------------------------------|----------------------------------------|---------------------------------|---------------------|-----------------------|
| Not yet due for the booster dose                       | 29 (42.6%)                            | 159 (54.6%)                     | 188 (48.1%)         | -4.792                |
| Recent COVID-19 infection                              | 8 (11.8%)                             | 20 (6.9%)                       | 28 (7.1%)           | Not significant       |
| Unavailable vaccine                                    | 9 (13.2%)                             | 32 (11%)                        | 41 (10.4%)          | Not significant       |
| Doesn't believe in the effectiveness of the vaccine    | 10 (14.7%)                            | 14 (4.8%)                       | 24 (6.1%)           | Not significant       |
| COVID-19 doesn't exist now                             | 4 (5.9%)                              | 11 (3.8%)                       | 15 (3.8%)           | Not significant       |
| No trust in the government                             | 1 (1.5%)                              | 1 (0.3%)                        | 2 (0.5%)            | Not significant       |
| Vaccine center is too far away                         | 4 (5.9%)                              | 2 (0.7%)                        | 6 (1.5%)            | 2.107                 |
| Unaware about the booster dose                         | 3 (4.4%)                              | 26 (9%)                         | 31 (7.9%)           | -2.193                |
| Felt that the booster is not necessary presently       | -                                      | 6 (2%)                          | 6 (1.5%)            | Not significant       |
| AEFI                                                   | -                                      | 2 (0.7%)                        | 2 (0.5%)            | Not significant       |
| Will take the vaccine soon                             | -                                      | 18 (6.2%)                       | 18 (4.5%)           | -2.703                |
| Others                                                 | -                                      | 32 (8.1%)                       | 393 (100%)          | Not significant       |
| TOTAL:                                                | 68 (100%)                             | 291 (100%)                      | 393 (100%)          |                       |

### TABLE 3: Reasons for not taking the COVID-19 booster dose (n = 393)
COVID-19: coronavirus disease-2019; AEFI: adverse events following immunization

254 respondents (46.2%) reported receiving a COVID-19 diagnosis (confirmed by reverse transcriptase-polymerase chain reaction testing) in the past with or without vaccination. Among them, 75 (29.7%) stated that they had COVID-19 before receiving a COVID-19 vaccine dose, 36 (14.6%) had COVID-19 after the first dose, 126 (51.2%) after the second dose, and 11 (4.5%) of them reported to have COVID-19 after taking the booster dose. Among the 75 respondents who had COVID-19 before receiving their first vaccine, 17.8% received the booster dose. Of the 36 respondents who had COVID-19 after their first dose, 22.2% received the booster dose. Of the 126 who had COVID-19 after the second dose, 29.3% received the booster dose.

Of the 11 respondents who had COVID-19 following the booster dose, 10 (91.0%) were medical professionals, four medical doctors, and six medical students. One of the 11 (9.1%) received the booster dose within three-to-six months of the second dose, three (27.3%) received it within six-to-nine months, six (54.5%) received it within nine-to-12 months, and one (9.1%) respondent received the booster dose 12-to-14 months after the second dose. Only one (9.0%) nonmedical subject developed COVID-19 following booster administration.
Of the 121 respondents who had associated comorbid conditions and other chronic illnesses, 31 (5.6%) had hypertension, 27 (4.9%) were obese/overweight, 24 (4.4%) had diabetes, seven (1.3%) had asthma, and the remaining had two or more comorbid/chronic illnesses in combination. Twenty-one (17.4%) respondents with comorbidities were from the medical and allied sectors, whereas 100 (82.6%) were from nonmedical sectors. Among the respondents with existing comorbidities, 40 (33.1%) received the booster dose.

Of the 21 respondents who were medical and allied professionals with existing comorbidities, 12 (57.1%) received the booster dose, 10 of whom had a history of COVID-19. Nine respondents (42.9%) did not receive the booster dose, of whom five had a history of COVID-19. There was no statistical significance observed between the two groups that had and had not taken the booster dose. Of the 100 respondents from various nonmedical sectors, 28 (28%) received the booster dose. Among them, 15 had a history of COVID-19. Seventy-two (42.9%) respondents did not receive the booster dose, and 56 had a history of COVID-19. There was no statistical significance observed.

Of the 155 respondents from the various medical and allied professions, 156 (87.7%) claimed to continue following COVID-19 precautionary behavior (e.g., social distancing, mask-wearing, and hand hygiene). Of the 395 respondents from nonmedical fields, 361 (91.4%) followed COVID-19 precautionary behavior. However, there was no statistical significance between the groups. Of the 53 respondents who reported not following COVID-19 precautionary behavior, 24 (45.3%) were aged 18 to 30, 11 (20.8%) were aged 41 to 50, nine (17%) were aged 51 to 60, and nine (17%) were age 51 to 60. All respondents aged 61 and older reported following COVID-19 precautionary behavior. Twelve (9.9%) of the 121 respondents with preexisting comorbid conditions/chronic illnesses reported not following COVID-19 precautionary behavior, while 41 (9.6%) of the 429 without existing comorbidities did not follow COVID-19 precautionary behavior. There was no statistical significance observed.

Of the 11 respondents who had COVID-19 following the booster dose, three of them (27.3%) reported not adhering to COVID-19 precautionary behavior.

**Discussion**

The COVID-19 vaccine was introduced in India in January 2021 for health care workers and frontline workers; those aged 18 and older were eligible for the vaccine in April 2021. Children and adolescents in India are not due for their booster dose because the COVID-19 vaccine's initial dose was introduced only in March 2022 for this age group [4, 16, 17]. COVID-19 vaccines are critical in preventing SARS-CoV-2 infection and severe COVID-19-related outcomes [18, 19].

In January 2022, the booster dose (precautionary dose) was made available to high-risk individuals (e.g., doctors and frontline workers) to boost their waning immunity [7]. Booster eligibility was later extended to other groups. Covishield and Covaxin are currently approved for booster doses in India [5]. Mixing COVID-19 vaccines was not allowed in India, meaning the precaution dose must be the same as the first and second doses during the study [20].

Most respondents received Covishield, which is not surprising because Covishield is the predominant vaccine administered in India, covering 80% of the market share [21]. Most respondents received two doses of the COVID-19 vaccine, while only 28% received the booster dose. The higher coverage in the present study was observed because the respondents were predominantly in medical professions. However, coverage of the booster in India among the general population is reported to be only 2.5% as of June 6, 2022 [6].

While medical professionals had higher uptake of the booster dose (more than 50%) than the nonmedical respondents (<20%), we found that nearly half of surveyed medical professionals have yet to take the booster dose. A significant number of medical professionals stated that they were not yet due for their booster, which was surprising because the first and second doses of the Covishield vaccine had to be taken one month apart as per the initial guidelines for the frontline workers [22]. This could be attributed to the general hesitancy to take the vaccine at the time of its announcement due to which the subsequent administration of the booster dose was unexpectedly delayed even among medical professionals [23]. However, further analysis regarding the same could not be conducted as the data on when each respondent received the initial doses of the COVID-19 vaccines were not collected.

Among the rest of the respondents from medical and allied professions who did not receive the booster, some did not believe in the efficacy of the vaccine, some did not believe that COVID-19 existed anymore, some claimed that the booster dose was unavailable, and others were entirely unaware of the announcement of the booster dose. All these reported reasons point to the failure of India’s Behavior Control Communication (BCC) strategies regarding the COVID-19 vaccination program. The BCC is an integrated and interactive process with communities to develop tailored messages and approaches using a variety of communication channels to develop positive behaviors; promote and sustain individual, community, and societal behavior change; and maintain appropriate behaviors regarding COVID-19 safety. India has implemented various strategies such as the BCC to ensure public awareness of COVID-19 and its vaccines [24].

Most of the remaining respondents (mostly nonmedical professionals) claimed that they were not yet due for their booster dose, but this could be because the booster dose was announced only one month prior to our survey (April 10, 2022) for individuals aged 18 or older in India [8]. Thus, hesitancy may not have been the main reason for the low coverage of the booster dose in the public. This contrasts with the previous doses of the vaccines, where hesitancy was the main governing factor for the low vaccination rates [11].
Another reason for the lower uptake of the booster dose among the nonmedical professionals than medical and allied professionals could be better awareness of their occupational risk and coexisting comorbid status, generating a greater perceived need by the medical professionals. Other factors influencing the lesser coverage of the booster in nonmedical professionals could be the general misinformation regarding the time gap between the administration of booster and the second dose of the COVID-19 vaccines and reduced fear of the disease due to the plateauing of cases in the country following the Omicron wave [25,26].

The percentage of respondents who developed COVID-19 following the booster dose were similar regardless of the time interval between the second dose and the booster dose as presented in Table 2. Thus, we conclude that there was no significant impact due to the time of administration of the booster dose (with respect to the second dose) on the rates of development of COVID-19. The Government of India’s move to set the eligibility for booster dose administration as nine months or later appears to be a sound strategy as the interval following the second dose has not impacted the occurrence of SARS-CoV-2 infection [7].

Following the booster dose, only 11 respondents developed COVID-19, most of whom were from medical and allied sectors. Furthermore, among the medical and nonmedical professionals who received the booster dose during the same period, the rate of development of COVID-19 was higher among medical and allied professionals. Therefore, the significant occupational risk of medical professionals was the leading cause of COVID-19 following the booster dose among these respondents [27].

The current study revealed that medical professionals were slightly less inclined (12.1%) to follow COVID-19 precautionary behavior than professionals from other sectors (8%). However, there was no statistical significance observed for the same.

Our study had several significant limitations. The main limitation of this study was that only urban and educated parts of Indian society with access to technology could access the survey and participate, meaning there was an inherent selection bias with the sampling technique. Performance bias was also another significant limitation. Larger studies covering the entire country with equal representation of all the states would provide deeper insights into the situation. As the booster dose was announced for the general population only one month prior to our survey, it is imperative to conduct future studies to reassess the situation of booster uptake in the country.

Conclusions
The coverage of COVID-19 booster doses was low among the respondents, including medical professionals. The booster dose has been effective in preventing COVID-19. Most respondents followed COVID-19 precautionary behavior despite the decline of active cases of COVID-19 in India following the Omicron wave. Our results indicate a need to strengthen public strategies to affect behavioral changes, such as improving the Indian BCC program, to ensure adequate coverage of the booster dose.

Appendices
The survey instrument used in the study
This is an online survey entitled: ‘Coverage of COVID-19 Booster (Precautionary) Dose in the Adult Population’ being conducted by a group of 4th-year medical students from Kempegowda Institute of Medical Sciences, Bangalore. We intend to study the public acceptance for the COVID-19 precautionary dose vaccines. The survey will take around 5 to 10 minutes of your time.

The questions are related to the demographics of the respondents and their familiarity with the COVID-19 vaccination.

If you have any queries related to the questionnaire- please feel free to contact the undersigned.

We thank you for your time and cooperation!

Anagha Brahmajosyula
Aniket Khamar
Deepika Kondath
Lavanya Bilichod
Namita Acharya
- 4th year MBBS, Kempegowda Institute of Medical Sciences, Bangalore.

INFORMED CONSENT:

PARTICIPATION
Your participation in this survey is purely voluntary. We assure you, your identity would be strictly anonymous and the information provided in the questionnaire would be used only for academic purposes.

* Required
1. Gender *(Mark only one oval.)*
   - Male
   - Female
   - Transgender
   - Prefer not to say

2. Age *(Mark only one oval.)*
   - 18-30
   - 31-40
   - 41-50
   - 51-60
   - 61-70
   - 71-80
   - 81 and above

3. Education *(Mark only one oval.)*
   - Professional degree (PhD scholar) / Postgraduate
   - Graduate
   - Undergraduate
   - 12th pass/ 2nd PUC
   - High school (8th to 10th grade)
   - Middle school (6th to 8th grade)
   - Primary school (1st to 5th grade)
   - Other:

4. Location *(this form is applicable only for those living in India) *(Mark only one oval.)*
   - Andhra Pradesh
   - Arunachal Pradesh
   - Assam
   - Bihar
   - Chhattisgarh
   - Goa
   - Gujarat
   - Haryana
   - Himachal Pradesh
   - Jharkhand
   - Karnataka
o Kerala
o Madhya Pradesh
o Maharashtra
o Meghalaya
o Mizoram
o Nagaland
o Odisha
o Punjab
o Rajasthan
o Sikkim
o Tamil Nadu
o Telangana
o Tripura
o Uttar Pradesh
o Uttarakhand
o West Bengal
o Others: Please mention
5. Which city do you live in? (Please mention) *
6. Occupation * (Mark only one oval.)
   o Medical student
   o Paramedics
   o Paramedical student
   o Student (engineering, commerce, etc.)
   o Business sector
   o Agriculture, animals, environmental sector
   o IT, civil engineering, automation, telecommunication, aeronautics
   o Education (Teacher/Professor)
   o Industrial workers, production, manufacture
   o Housekeeping and cleaning industry
   o Driver, Transport industry, Aviation industry
   o Housewife
   o Public service/government job
   o Media, journalism, graphics, printing, design
   o Marketing, PR, advertising
   o Legal, Administration
7. Have you taken the COVID-19 Vaccine? * (Mark only one oval.)
- No vaccine taken
- 1st dose taken
- 2 doses taken

8. Which vaccine have you taken? (Mark only one oval.)
- CoviShield (Oxford AstraZeneca)
- Covaxin
- Sputnik V
- Pfizer
- Moderna
- Other:

9. Have you taken the booster dose? * (Mark only one oval.)
- Yes
- No

10. If yes, how many days after the 2nd dose did you take the booster dose? (Mark only one oval.)
- 1-5 months
- 3-6 months
- 6-9 months
- 9-12 months
- 12-14 months
- Greater than 14 months

11. If no, why? (i.e., If you have not taken the booster dose) (Check all that apply.)
- Not yet due for the booster dose
- Recent COVID infection so you don’t believe you need the vaccine
- Unavailable vaccine
- Doesn’t believe in the effectiveness of vaccine
Believes that COVID-19 doesn’t exist anymore
No trust in the government
Economic reasons
Vaccine center is too far away
Unaware about the booster dose
Adverse effects with any previous dose
Other:

12. If you have taken the booster dose, how many days has it been since the booster dose has been given? (Mark only one oval.)
Less than a month
1 month
2 months
3 months
Greater than 3 months

13. Have you had a COVID-19 infection / COVID-19 like symptoms anytime in the past? * (Mark only one oval.)
No
Yes

14. If yes, when was it? (Mark only one oval.)
Before any vaccine
After 1st vaccine dose
After 2nd vaccine dose
After the booster dose

15. Have you been diagnosed with any of the following? * (Check all that apply.)
Diabetes
Hypertension
Overweight/obesity
Asthma
None
Other:

16. Do you continue to follow COVID-19 precautionary behaviour? (i.e., wearing masks, using sanitizers, social distancing, etc.) * (Mark only one oval.)
Yes
No

Additional Information

Disclosures
Human subjects: Consent was obtained or waived by all participants in this study. Kempegowda Institute of Medical Sciences, Institutional Ethics Committee issued approval KIMS/IEC/A027/M/2022. The IEC approves
the above mentioned study titled 'Coverage of COVID-19 Booster Dose (Precautionary) in the Adult Population- An Online Survey.' The study has been cleared for publication. . Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Andrews MA, Areekul B, Rajesh KR, et al.: First confirmed case of COVID-19 infection in India: a case report. Indian J Med Res. 2020, 151:490-2. 10.4103/imr.IJMRR_2151_20

2. Novel coronavirus disease 2019 (COVID-19) pandemic: increased transmission in the EU/EAA and the UK - sixth update. (2020). Accessed: June 21, 2022: https://www.ecdc.europa.eu/sites/default/files/documents/RRA-sixth-update-Outbreak-of-novel-coronavirus-disease-2019-

3. WHO coronavirus (COVID-19) dashboard. (2021). Accessed: June 6, 2022: https://covid19.who.int/

4. "Landmark step": India set to rollout COVID vaccines from 16 Jan. (2021). Accessed: June 6, 2022: https://www.thedepartmentofhealth.gov.in/corona-vaccine-vaccination-campaign-in-india-16-january-

5. COVID-19 vaccine. (2021). Accessed: June 6, 2022: https://vaccine.imd.org.in/covid-19-vaccine.

6. "Tracking coronavirus vaccinations around the world." (2021). Accessed: June 6, 2022: https://www.nytimes.com/interactive/2021/world/covid-vaccinations-tracker.html

7. Guidelines for COVID-19 vaccination of children between 15-18 years and precaution dose to HCWs, FLWs & 60+ population with comorbidities. (2022). Accessed: June 6: https://www.mohfw.gov.in/pdf/GuidelinesforCOVID19VaccinationChildrenbetween15to18yearsandPrecautionDoseforHCWsFLWS60PlusTillJuly2022.pdf

8. Precaution dose to be available to 18+ from April 10: key points. (2022). Accessed: June 6, 2022: https://timesofindia.indiatimes.com/india/precaution-dose-to-be-available-to-all-from-april-10-key-points/articleshow...

9. Chenchula S, Karunakaran P, Sharma S, Chavan M: Current evidence on efficacy of COVID-19 booster dose vaccination against the Omicron variant. A systematic review. J Med Virol. 2022, 94:296-76. 10.1002/jmv.27697

10. List of states where COVID-19 mask not mandatory anymore. Explained. (2022). Accessed: June 6, 2022: https://www.hindustantimes.com/india-news/list-of-states-where-covid-19-mask-not-mandatory-anymore-explained-101648780147

11. Gupta M, Goyal R, Aggarwal S, Singh M, Gupta VK, Garg N: Demographic and KAP determinants of COVID-19 vaccine hesitancy and vaccine refusal: a cross-sectional study in Indian population. Int J Community Med Public Health. 2021, 8:4776-85. 10.18203/2394-6040.ijcmph202135664

12. Bar-On YM, Goldberg Y, Mandel M, et al.: Protection of BNT162b2 vaccine booster against COVID-19 in Israel. N Engl J Med. 2021, 385:1393-400. 10.1056/NEJMoa2114255

13. Voysey M, Costa Lemmens SA, Madhi SA, et al.: Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021, 397:881-91. 10.1016/S0140-6736(21)00432-3

14. Sanderse RM, Vistinen HT, Dinesen PT, Østergaard SD: COVID-19 booster vaccine willingness. Dan Med J. 2021, 69:A10210765.

15. COVID-19 vaccines operational guidelines. (2021). Accessed: June 6, 2022: https://main.mohfw.gov.in/newhighlights-51

16. India to start COVID vaccination registration for people above 18 years from April 28 . (2022). Accessed: June 6, 2022: https://economictimes.indiatimes.com/news/india/covid-vaccination-registration-for-above-18-starts-from-april-28/arti...

17. Vaccination of 12-14-year-olds starts tomorrow. (2022). Accessed: June 6, 2022: https://economictimes.indiatimes.com/news/india/vaccination-of-12-14-year-olds-starts-tomorrow/articleshow/90210263.cms

18. Lopez Bernal J, Andrews N, Gower C, et al.: Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ. 2021, 373:n1088. 10.1136/bmj.n1088

19. Mathi R, Hebbar G: COVID-19 vaccination and breakthrough infections among healthcare workers: an online survey. Int J Community Med Public Health. 2021, 8:5435-40. 10.18203/2394-6040.ijcmph20214284

20. Govt may not allow mixing of COVID-19 vaccines for booster shots: report . (2022). Accessed: June 6, 2022: https://www.businessstoday.in/coronavirus/story/govt-may-not-allow-mixing-of-covid-19-vaccines-for-booster-shots-repo...

21. India’s ‘other’ COVID vaccines: the status of under-trial, approved and unused jabs . (2022). Accessed: June 25, 2022: https://www.thehindu.com/sci-tech/health/indias-other-covid-vaccines-status-of-under-trial-approved-but-unused-jabs-a/

22. Frequently asked questions. (2021). Accessed: June 6, 2022: https://www.unicef.org/india/coronavirus/covid-19-faq.

23. Danabah KG, Magreh SS, Saravanan S, Gopichandran V: Attitude towards COVID 19 vaccines and vaccine hesitancy in urban and rural communities in Tamil Nadu, India - a community based survey. BMC Health Serv Res. 2021, 21:994. 10.1186/s12913-021-05075-4

24. Reddy BV, Gupta A: Importance of effective communication during COVID-19 infodemic . J Family Med Prim Care. 2020, 9:5795-6. 10.4103/ijpmc.ijpmc_719_20

25. Jairoun AA, Al-Hemyari SS, El-Dahiyat F, et al.: Assessing public knowledge, attitudes and determinants of third COVID-19 vaccine booster dose acceptance: current scenario and future perspectives. J Pharm Policy Pract. 2022, 15:26. 10.1186/s13145-022-00422-2

26. Covid-19: Centre calls India’s situation ‘optimistic’, but warns against complacency . (2022). Accessed: June 23, 2022: https://www.financialexpress.com/lifestyle/health/covid-19-centre-calls-indias-situation-optimistic-but-warns-against-101648780147

27. Nguyen LH, Drew DA, Graham MS, et al.: Risk of COVID-19 among front-line health-care workers and the general community: a prospective cohort study. Lancet Public Health. 2020, 5:e475-83. 10.1016/S2468-
